比卡魯胺
參考文獻

1 2  Finkel R, Clark MA, Cubeddu LX. . Lippincott Williams & Wilkins. 2009: 481–. ISBN 978-0-7817-7155-9.
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15  Cockshott ID. . Clinical Pharmacokinetics. 2004, 43 (13): 855–878. PMID 15509184. S2CID 29912565. doi:10.2165/00003088-200443130-00003.
1 2 3 4 5 6 7  Dart RC. . Lippincott Williams & Wilkins. 2004: 497, 521. ISBN 978-0-7817-2845-4. （原始内容存档于11 May 2016）.
1 2 3 4 5 6 7 8  Lemke TL, Williams DA. . Lippincott Williams & Wilkins. 2008: 121, 1288, 1290. ISBN 978-0-7817-6879-5. （原始内容存档于2017-09-08）.
↑  Grosse L, Campeau AS, Caron S, Morin FA, Meunier K, Trottier J, Caron P, Verreault M, Barbier O. . Basic & Clinical Pharmacology & Toxicology. August 2013, 113 (2): 92–102. PMC 3815647 . PMID 23527766. doi:10.1111/bcpt.12071.
↑  Dole EJ, Holdsworth MT. . The Annals of Pharmacotherapy. 1997, 31 (1): 65–75. PMID 8997470. S2CID 20347526. doi:10.1177/106002809703100112. page 67: Currently, information is not available regarding the activity of the major urinary metabolites of bicalutamide, bicalutamide glucuronide, and hydroxybicalutamide glucuronide.
↑  Schellhammer PF. . Expert Opinion on Pharmacotherapy. September 2002, 3 (9): 1313–28. PMID 12186624. S2CID 32216411. doi:10.1517/14656566.3.9.1313. The clearance of bicalutamide occurs pre- dominantly by hepatic metabolism and glucuronidation, with excretion of the resulting inactive metabolites in the urine and faces.
1 2 3  Skidmore-Roth L. . Elsevier Health Sciences. 2013-04-17: 193–194  [2016-09-27]. ISBN 978-0-323-22267-9. （原始内容存档于2023-01-14）.
↑  Jordan VC, Furr BJ. . Springer Science & Business Media. 2010-02-05: 350–. ISBN 978-1-59259-152-7. （原始内容存档于2016-05-29）.
1 2 3 4 5 6 7 8 9  . The American Society of Health-System Pharmacists.   [2016-12-08]. （原始内容存档于2016-12-29）.
↑  Wass JA, Stewart PM. . OUP Oxford. 2011-07-28: 1625–. ISBN 978-0-19-923529-2. （原始内容存档于2016-05-11）.
↑  Shergill I, Arya M, Grange PR, Mundy AR. . Springer Science & Business Media. 2010: 40. ISBN 9781848827042. （原始内容存档于28 October 2014） （英语）.
1 2 3 4 5 6 7 8  Wellington K, Keam SJ.  (PDF). Drugs. 2006, 66 (6): 837–50  [2016-08-13]. PMID 16706554. S2CID 46966712. doi:10.2165/00003495-200666060-00007. （原始内容 (PDF)存档于2016-08-28）.
1 2  Williams H, Bigby M, Diepgen T, Herxheimer A, Naldi L, Rzany B. . John Wiley & Sons. 2009-01-22: 529–. ISBN 978-1-4443-0017-8. （原始内容存档于2016-05-02）.
↑  Carvalho RM, Santos LD, Ramos PM, Machado CJ, Acioly P, Frattini SC, Barcaui CB, Donda AL, Melo DF. . J Cosmet Dermatol. January 2022, 21 (10): 4171–4175. PMID 35032336. S2CID 253239337. doi:10.1111/jocd.14773.
1 2  Yuan J, Desouza R, Westney OL, Wang R. . Asian Journal of Andrology. 2008, 10 (1): 88–101. PMID 18087648. doi:10.1111/j.1745-7262.2008.00314.x .
↑  Elliott S, Latini DM, Walker LM, Wassersug R, Robinson JW. . The Journal of Sexual Medicine. 2010, 7 (9): 2996–3010. PMID 20626600. doi:10.1111/j.1743-6109.2010.01902.x.
↑  Hammerer P, Manka L. . . Springer International Publishing. 2019: 255–276. ISBN 978-3-319-42622-8. doi:10.1007/978-3-319-42623-5_77. Bicalutamide is the most widely used antiandrogen in the treatment of prostate cancer. [...] Common side effects [of bicalutamide] include breast enlargement, breast tenderness, hot flashes, and constipation as well as feminization and changes in mood and liver as well as lung toxicity; monitoring of liver enzymes is recommended during treatment (Schellhammer and Davis 2004).
↑  Droz J, Audisio RA. . Springer Science & Business Media. 2012-10-02: 84–. ISBN 978-0-85729-986-4. （原始内容存档于2016-05-11）.
↑  Shapiro J. . Elsevier Health Sciences. 2012-11-12: 187–. ISBN 978-1-4557-7169-1.
1 2  Jia AY, Spratt DE. . Int J Radiat Oncol Biol Phys. June 2022, 113 (2): 316–319. PMID 35569476. S2CID 248765294. doi:10.1016/j.ijrobp.2022.01.037. Four other randomized trials using BICmono have also raised concerns about either lack of efficacy or even harm from this treatment approach compared with placebo or no hormone therapy. SPCG-6 randomized 1218 patients to either 150 mg of BICmono daily or placebo. In the subset of patients with LPCa managed with observation, survival was significantly worse with BIC than placebo (hazard ratio [HR], 1.47; 95% confidence interval, 1.06-2.03).10 Two other randomized trials were part of the early prostate cancer program,11 which conducted 3 randomized trials that were pooled together to determine the benefit of BICmono (SPCG-6 was one of the 3 trials). Overall, in the combined 8113 patient pooled cohort, after a median follow-up of 7 years, there was no improvement even in progression-free survival from the use of adjuvant BIC in LPCa, and there was a trend for worse overall survival (HR, 1.16; 95% confidence interval, 0.99-1.37; P = .07). [...] Although not in LPCa, NRG/RTOG 9601 demonstrated findings consistent with the prior trials.12 This trial randomized men to postprostatectomy salvage radiation therapy plus placebo versus 150 mg of BICmono daily for 2 years. After a median follow-up of 13 years, the trial showed that there were significantly more grade 3 to 5 cardiac events in the BICmono arm. In patients with less aggressive disease with lower PSAs (prostate-specific antigens; more analogous to LPCa), other-cause mortality was significantly higher in the BICmono arm. In patients with high PSAs >1.5 ng/mL (which with modern molecular positron emission tomography imaging would be expected to have high rates of regional and distant metastatic disease), a survival benefit from the addition of BIC was observed. This is consistent with results from the early prostate cancer studies that showed that only patients with more advanced disease derived benefit from BICmono.10 Thus, all the randomized evidence from 5 trials (Table 1) demonstrates that, in LPCa, BICmono had no clinically significant oncologic activity over placebo/no treatment, and consistent trends with long-term use resulted in worse survival.
1 2 3 4 5 6  . DailyMed. 2019-09-01  [2020-05-07]. （原始内容存档于2020-07-27）.
↑  Lee K, Oda Y, Sakaguchi M, Yamamoto A, Nishigori C. . Photodermatology, Photoimmunology & Photomedicine. May 2016, 32 (3): 161–4. PMID 26663090. S2CID 2761388. doi:10.1111/phpp.12230.
↑  Lee K,  et al. . Reactions Weekly. 2016, 1612 (1): 161–4. PMID 26663090. S2CID 261402820. doi:10.1007/s40278-016-19790-1.
↑  Singh SM, Gauthier S, Labrie F. . Current Medicinal Chemistry. February 2000, 7 (2): 211–47. PMID 10637363. doi:10.2174/0929867003375371.
↑  Furr BJ, Tucker H. . Urology. January 1996, 47 (1A Suppl): 13–25; discussion 29–32. PMID 8560673. doi:10.1016/S0090-4295(96)80003-3.
↑  Fischer J, Ganellin CR. . John Wiley & Sons. 2006: 515  [2017-08-24]. ISBN 9783527607495. （原始内容存档于2023-01-12） （英语）.
↑  World Health Organization. . Geneva: World Health Organization. 2019. hdl:10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
↑  Hamilton R. . Jones & Bartlett Learning. 2015: 381. ISBN 9781284057560.
1 2 3 4  . Drugs.com.   [2016-08-13]. （原始内容存档于2016-09-18）.
1 2  Akaza H. . Gan to Kagaku Ryoho. Cancer & Chemotherapy. 1999, 26 (8): 1201–7. PMID 10431591 （日语）.
1 2   (PDF). AstraZeneca.   [2017-07-01]. （原始内容存档 (PDF)于2017-09-09）.
↑  Bagatelle C, Bremner WJ. . Springer Science & Business Media. 2003-05-27: 25–. ISBN 978-1-59259-388-0.
↑  Klotz L, Schellhammer P. . Clinical Prostate Cancer. March 2005, 3 (4): 215–9. PMID 15882477. doi:10.3816/cgc.2005.n.002.
↑  Schellhammer PF, Sharifi R, Block NL, Soloway MS, Venner PM, Patterson AL, Sarosdy MF, Vogelzang NJ, Schellenger JJ, Kolvenbag GJ. . Urology. September 1997, 50 (3): 330–6. PMID 9301693. doi:10.1016/S0090-4295(97)00279-3.
1 2  Suzuki H, Kamiya N, Imamoto T, Kawamura K, Yano M, Takano M, Utsumi T, Naya Y, Ichikawa T. . International Journal of Clinical Oncology. October 2008, 13 (5): 401–10. PMID 18946750. S2CID 32859879. doi:10.1007/s10147-008-0830-y.
↑  Usami M, Akaza H, Arai Y, Hirano Y, Kagawa S, Kanetake H, Naito S, Sumiyoshi Y, Takimoto Y, Terai A, Yoshida H, Ohashi Y. . Prostate Cancer Prostatic Dis. 2007, 10 (2): 194–201. PMID 17199134. doi:10.1038/sj.pcan.4500934 . In most countries, bicalutamide is given at a dose of 50 mg when used in combination with an LHRH-A. However, based on pharmacokinetic and pharmacodynamic data, the approved dose of bicalutamide in Japanese men is 80 mg per day.
↑  Melmed S. . Elsevier Health Sciences. 2016-01-01: 752–. ISBN 978-0-323-29738-7. GnRH analogues, both agonists and antagonists, severely suppress endogenous gonadotropin and testosterone production [...] Administration of GnRH agonists (e.g., leuprolide, goserelin) produces an initial stimulation of gonadotropin and testosterone secretion (known as a "flare"), which is followed in 1 to 2 weeks by GnRH receptor downregulation and marked suppression of gonadotropins and testosterone to castration levels. [...] To prevent the potential complications associated with the testosterone flare, AR antagonists (e.g., bicalutamide) are usually coadministered with a GnRH agonist for men with metastatic prostate cancer.399
↑  Sugiono M, Winkler MH, Okeke AA, Benney M, Gillatt DA. . Prostate Cancer and Prostatic Diseases. 2005, 8 (1): 91–4. PMID 15711607. doi:10.1038/sj.pcan.4500784 .
↑  Erem C. . Acta Clinica Belgica. 2013, 68 (4): 268–74. PMID 24455796. S2CID 39120534. doi:10.2143/ACB.3267.
↑  Ascenso A, Marques HC. . Mini Reviews in Medicinal Chemistry. January 2009, 9 (1): 1–10. PMID 19149656. doi:10.2174/138955709787001730.
↑  Kaur S, Verma P, Sangwan A, Dayal S, Jain VK. . Indian Journal of Dermatology. 2016, 61 (4): 403–7. PMC 4966398 . PMID 27512185. doi:10.4103/0019-5154.185703 .
↑  Lotti F, Maggi M. . . 2015: 1451–1464. ISBN 978-3-662-45138-0. doi:10.1007/978-3-662-45139-7_142.
↑  Müderris II, Öner G.  [Flutamide and Bicalutamide Treatment in Hirsutism]. Turkiye Klinikleri Journal of Endocrinology-Special Topics. 2009, 2 (2): 110–2  [2019-03-28]. ISSN 1304-0529. （原始内容存档于2020-07-27） （土耳其语）.
↑  Moretti C, Guccione L, Di Giacinto P, Simonelli I, Exacoustos C, Toscano V, Motta C, De Leo V, Petraglia F, Lenzi A. . J. Clin. Endocrinol. Metab. March 2018, 103 (3): 824–838. PMID 29211888. doi:10.1210/jc.2017-01186 .
↑  Randolph JF. . Clin Obstet Gynecol. December 2018, 61 (4): 705–721. PMID 30256230. S2CID 52821192. doi:10.1097/GRF.0000000000000396.
↑  Fishman SL, Paliou M, Poretsky L, Hembree WC. . . Contemporary Endocrinology. 2019: 143–163. ISBN 978-3-030-05682-7. ISSN 2523-3785. S2CID 86772102. doi:10.1007/978-3-030-05683-4_8.
↑  Neyman A, Fuqua JS, Eugster EA. . The Journal of Adolescent Health. April 2019, 64 (4): 544–546. PMC 6431559 . PMID 30612811. doi:10.1016/j.jadohealth.2018.10.296.
↑  Gooren LJ. . The New England Journal of Medicine. March 2011, 364 (13): 1251–1257. PMID 21449788. doi:10.1056/nejmcp1008161.
↑  Deutsch M.  (PDF) 2nd. University of California, San Francisco: Center of Excellence for Transgender Health. 2016-06-17: 28  [2023-06-09]. （原始内容存档 (PDF)于2023-05-30）.
↑  Vincent B. . Jessica Kingsley Publishers. 2018-06-21: 158–  [2019-01-01]. ISBN 978-1-78450-475-5. （原始内容存档于2023-01-14）.
↑  Wierckx K, Gooren L, T'Sjoen G. . The Journal of Sexual Medicine. May 2014, 11 (5): 1240–1247. PMID 24618412. doi:10.1111/jsm.12487.
↑  Schoelwer M, Eugster EA. . . Endocrine Development 29. 2015: 230–239. ISBN 978-3-318-02788-4. PMC 5345994 . PMID 26680582. doi:10.1159/000438895.
↑  Haddad NG, Eugster EA. . Best Practice & Research. Clinical Endocrinology & Metabolism. June 2019, 33 (3): 101273. PMID 31027974. S2CID 135410503. doi:10.1016/j.beem.2019.04.007. hdl:1805/19111 .
↑  Haddad NG, Eugster EA. . . 2012: 1199–1212. ISBN 978-1-4419-1794-2. doi:10.1007/978-1-4419-1795-9_71.
↑  Zacharin M. . . Handbook of Experimental Pharmacology 261. 2019: 507–538. ISBN 978-3-030-50493-9. ISSN 0171-2004. PMID 31144045. S2CID 169040406. doi:10.1007/164_2019_208.
↑  Kliegman RM, Stanton B, St Geme J, Schor NF. . Elsevier Health Sciences. 17 April 2015: 2661–  [2016-09-27]. ISBN 978-0-323-26352-8. （原始内容存档于2023-01-12）.
↑  Jameson JL, De Groot LJ. . Elsevier Health Sciences. 25 February 2015: 2425–2426, 2139. ISBN 978-0-323-32195-2.
↑  Levey HR, Kutlu O, Bivalacqua TJ. . Asian Journal of Andrology. January 2012, 14 (1): 156–163. PMC 3753435 . PMID 22057380. doi:10.1038/aja.2011.114.
↑  Broderick GA, Kadioglu A, Bivalacqua TJ, Ghanem H, Nehra A, Shamloul R. . The Journal of Sexual Medicine. January 2010, 7 (1 Pt 2): 476–500. PMID 20092449. doi:10.1111/j.1743-6109.2009.01625.x.
↑  Chow K, Payne S. . BJU International. December 2008, 102 (11): 1515–1521. PMID 18793304. S2CID 35399393. doi:10.1111/j.1464-410X.2008.07951.x .
↑  Dahm P, Rao DS, Donatucci CF. . Urology. January 2002, 59 (1): 138. PMID 11796309. doi:10.1016/S0090-4295(01)01492-3.
↑  Gooren LJ. . The Journal of Clinical Endocrinology & Metabolism. 2011, 96 (12): 3628–37. PMID 21956411. doi:10.1210/jc.2011-1540 .
↑  Giltay EJ, Gooren LJ. . The Journal of the American Academy of Psychiatry and the Law. 2009, 37 (1): 53–8. PMID 19297634.
↑  Khan O, Mashru A. . Current Opinion in Endocrinology, Diabetes and Obesity. 2016, 23 (3): 271–8. PMID 27032060. S2CID 43286710. doi:10.1097/MED.0000000000000257.
↑  . American Psychiatric Pub. 1999: 111–. ISBN 978-0-89042-280-9.
↑  Houts FW, Taller I, Tucker DE, Berlin FS. . Advances in Psychosomatic Medicine. 2011, 31: 149–63. ISBN 978-3-8055-9825-5. PMID 22005210. doi:10.1159/000330196.
↑  Rousseau L, Couture M, Dupont A, Labrie F, Couture N. . The Canadian Journal of Psychiatry. 1990, 35 (4): 338–41. PMID 2189544. S2CID 28970865. doi:10.1177/070674379003500412.
1 2 3  Swiss Pharmaceutical Society (编). . Taylor & Francis. January 2000: 123–. ISBN 978-3-88763-075-1. （原始内容存档于2016-04-24）.
↑  Sweetman SC. . Pharmaceutical Press. 2011: 750–751  [2016-09-27]. ISBN 978-0-85369-933-0. （原始内容存档于2023-01-14）.
1 2  Chabner BA, Longo DL. . Lippincott Williams & Wilkins. 2010-11-08: 679–680  [2016-09-27]. ISBN 978-1-60547-431-1. （原始内容存档于2023-01-10）. From a structural standpoint, antiandrogens are classified as steroidal, including cyproterone [acetate] (Androcur) and megestrol [acetate], or nonsteroidal, including flutamide (Eulexin, others), bicalutamide (Casodex), and nilutamide (Nilandron). The steroidal antiandrogens are rarely used.
1 2  . TGA. （原始内容存档于2016-09-14）.
1 2  Iswaran TJ, Imai M, Betton GR, Siddall RA. . The Journal of Toxicological Sciences. May 1997, 22 (2): 75–88. PMID 9198005. doi:10.2131/jts.22.2_75 .
1 2  Smith RE. . Bentham Science Publishers. 2013-04-04: 306–. ISBN 978-1-60805-149-6. （原始内容存档于2016-05-29）.
↑  Skeel RT, Khleif SN. . Lippincott Williams & Wilkins. 2011: 724–. ISBN 9781608317820. （原始内容存档于2016-05-29）.
1 2  Wirth MP, Hakenberg OW, Froehner M. . European Urology. February 2007, 51 (2): 306–13; discussion 314. PMID 17007995. doi:10.1016/j.eururo.2006.08.043.
↑  Wellington K, Keam SJ. . Drugs. 2006, 66 (6): 837–50. PMID 16706554. S2CID 46966712. doi:10.2165/00003495-200666060-00007.
1 2  Lehne RA. . Elsevier Health Sciences. 2013: 1297–  [2016-09-27]. ISBN 978-1-4377-3582-6. （原始内容存档于2023-01-10）.
1 2 3  Kolvenbag GJ, Blackledge GR. . Urology. January 1996, 47 (1A Suppl): 70–9; discussion 80–4. PMID 8560681. doi:10.1016/s0090-4295(96)80012-4. Bicalutamide is a new antiandrogen that offers the convenience of once-daily administration, demonstrated activity in prostate cancer, and an excellent safety profile. Because it is effective and offers better tolerability than flutamide, bicalutamide represents a valid first choice for antiandrogen therapy in combination with castration for the treatment of patients with advanced prostate cancer.
↑  Resnick MI, Thompson IM. . PMPH-USA. 2000: 379–. ISBN 978-1-55009-102-1. （原始内容存档于2016-06-10）.
↑  Iversen P, Johansson JE, Lodding P, Lukkarinen O, Lundmo P, Klarskov P, Tammela TL, Tasdemir I, Morris T, Carroll K. . The Journal of Urology. November 2004, 172 (5 Pt 1): 1871–6. PMID 15540741. doi:10.1097/01.ju.0000139719.99825.54.
↑  Wellington K, Keam SJ. . Drugs. 2006, 66 (6): 837–50. PMID 16706554. S2CID 46966712. doi:10.2165/00003495-200666060-00007.
↑  Iversen P, Johansson JE, Lodding P, Kylmälä T, Lundmo P, Klarskov P, Tammela TL, Tasdemir I, Morris T, Armstrong J. . Scandinavian Journal of Urology and Nephrology. 2006, 40 (6): 441–52. PMID 17130095. S2CID 25862814. doi:10.1080/00365590601017329.
↑  Trüeb RM, Luu NC, Uribe NC, Régnier A. . J Cosmet Dermatol. December 2022, 21 (12): 7200–7201. PMID 35332669. S2CID 247677549. doi:10.1111/jocd.14936. Indeed, due to the minimal biological importance of androgens in women, the adverse effects of bicalutamide are few. And yet, bicalutamide has been associated with elevated liver enzymes, and as of 2021, there have been 10 case reports of liver toxicity associated with bicalutamide, with fatality occurring in 2 cases.2
↑  Gretarsdottir HM, Bjornsdottir E, Bjornsson ES. . Case Reports in Gastroenterology. 2018, 12 (2): 266–70. ISSN 1662-0631. doi:10.1159/000485175 . hdl:20.500.11815/1492 .
↑  Hussain S, Haidar A, Bloom RE, Zayouna N, Piper MH, Jafri SM. . Am J Case Rep. 2014, 15: 266–70. PMC 4068966 . PMID 24967002. doi:10.12659/AJCR.890679.
↑  Yun GY, Kim SH, Kim SW, Joo JS, Kim JS, Lee ES, Lee BS, Kang SH, Moon HS, Sung JK, Lee HY, Kim KH. . World J. Gastroenterol. April 2016, 22 (15): 4062–5. PMC 4823258 . PMID 27099451. doi:10.3748/wjg.v22.i15.4062 .
↑  . Elsevier. 2010-12-03: 44–45. ISBN 978-0-444-53631-0. （原始内容存档于2016-05-26）.
↑  Paoletti R. . Springer Science & Business Media. 6 December 2012: 218–  [2016-09-27]. ISBN 978-1-4684-7236-3. （原始内容存档于2023-01-14）.
↑  Papadimitriou K, Anagnostis P, Goulis DG. . . Elsevier. 2022: 297–314. ISBN 9780128230459. S2CID 244697776. doi:10.1016/B978-0-12-823045-9.00013-4.
↑  . Springhouse Corp. 2000  [2016-09-27]. ISBN 9780874349979. （原始内容存档于2023-01-14）.
↑  Tyrrell CJ, Iversen P, Tammela T, Anderson J, Björk T, Kaisary AV, Morris T. . BJU International. September 2006, 98 (3): 563–72. PMID 16771791. S2CID 41672303. doi:10.1111/j.1464-410X.2006.06275.x.
↑  Weber GF. . Springer. 2015-07-22: 318–. ISBN 978-3-319-13278-5. Compared to flutamide and nilutamide, bicalutamide has a 2-fold increased affinity for the Androgen Receptor, a longer half-life, and substantially reduced toxicities. Based on a more favorable safety profile relative to flutamide, bicalutamide is indicated for use in combination therapy with a Gonadotropin Releasing Hormone analog for the treatment of advanced metastatic prostate carcinoma.
↑  Denis L, Mahler C. . Urology. January 1996, 47 (1A Suppl): 26–8; discussion 29–32. PMID 8560674. doi:10.1016/S0090-4295(96)80004-5.
↑  Mohler ML, Bohl CE, Jones A, Coss CC, Narayanan R, He Y, Hwang DJ, Dalton JT, Miller DD. . Journal of Medicinal Chemistry. June 2009, 52 (12): 3597–617. PMID 19432422. doi:10.1021/jm900280m. [C]linically relevant antiandrogens currently are nonsteroidal anilide derivatives. Antiandrogens used for prostate cancer include the monoarylpropionamide flutamide (1) (a prodrug of hydroxyflutamide (2)),29–31 the hydantoin nilutamide(3),32–34 and the diarylpropionamide bicalutamide (4) (Chart1).35–37
1 2  McPherson EM.  3rd. William Andrew Publishing. 2013-10-22: 627, 1695. ISBN 978-0-8155-1856-3. （原始内容存档于2016-06-09）.
1 2 3  Tucker H, Crook JW, Chesterson GJ. . Journal of Medicinal Chemistry. 1988, 31 (5): 954–9. PMID 3361581. doi:10.1021/jm00400a011.
↑  James KD, Ekwuribe NN. . Synthesis. 2002, 2002 (7): 850–2. doi:10.1055/s-2002-28508.
↑  US application 2006/0041161,Pizzetti E, Vigano E, Lussana M, Landonio E,「Procedure for the synthesis of bicalutamide」,发表于2006-02-23  的存檔，存档日期2018-01-04.
↑  Chand M, Shukla AK.  (报告). 2012. SSRN 2160199 . doi:10.2139/ssrn.2160199 .
↑  Diamanti-Kandarakis E. . Current Pharmaceutical Design. September 1999, 5 (9): 707–23  [2016-09-27]. PMID 10495361. doi:10.2174/1381612805666230111201150. （原始内容存档于2023-01-10）. Several trials demonstrated complete clearing of acne with flutamide [62,77]. Flutamide used in combination with an [oral contraceptive], at a dose of 500mg/d, flutamide caused a dramatic decrease (80%) in total acne, seborrhea and hair loss score after only 3 months of therapy [53]. When used as a monotherapy in lean and obese PCOS, it significantly improves the signs of hyperandrogenism, hirsutism and particularly acne [48]. [...] flutamide 500mg/d combined with an [oral contraceptive] caused an increase in cosmetically acceptable hair density, in sex of seven women suffering from diffuse androgenetic alopecia [53].
↑  Denis LJ, Griffiths K, Kaisary AV, Murphy GP. . CRC Press. 1999-03-01: 55,279–280. ISBN 978-1-85317-422-3. （原始内容存档于2016-06-03）.
↑  Elks J. . Springer. 2014-11-14: 573–. ISBN 978-1-4757-2085-3. （原始内容存档于2016-05-15）.
↑  Furr BJ. . Hum Fertil (Camb). 1998, 1 (1): 56–63. PMID 11844311. doi:10.1080/1464727982000198131.
↑  Furr BJ. . Annals of the New York Academy of Sciences. June 1995, 761 (1): 79–96. Bibcode:1995NYASA.761...79F. PMID 7625752. S2CID 37242269. doi:10.1111/j.1749-6632.1995.tb31371.x.
↑  Cadilla R, Turnbull P. . Curr Top Med Chem. 2006, 6 (3): 245–70  [2019-12-11]. PMID 16515480. doi:10.2174/156802606776173456. （原始内容存档于2020-08-18）.
↑  Engel J, Kleemann A, Kutscher B, Reichert D.  5th. Thieme. 2009: 153–154. ISBN 978-3-13-179275-4.
↑  Furr BJ, Valcaccia B, Curry B, Woodburn JR, Chesterson G, Tucker H. . The Journal of Endocrinology. June 1987, 113 (3): R7–9. PMID 3625091. doi:10.1677/joe.0.113r007.
↑  . . （原始内容存档于26 November 2016）.
↑  Morton IK, Hal JM. . Springer Science & Business Media. 2012-12-06: 51–. ISBN 978-94-011-4439-1. （原始内容存档于2016-05-14）.
↑  Ganellin CR, Triggle DJ. . CRC Press. 1996-11-21: 570–. ISBN 978-0-412-46630-4. （原始内容存档于2016-05-07）.
↑  Ferraro MB, Orendt AM, Facelli JC. . Huang D, Jo K, Lee H, Kang H, Bevilacqua V  (编). . Lecture Notes in Computer Science 5754. Springer. 2009-09-19: 120–  [2016-09-27]. ISBN 978-3-642-04070-2. doi:10.1007/978-3-642-04070-2_14. （原始内容存档于2023-01-14）.
↑  Dhas NL, Ige PP, Kudarha RR. . Powder Technology. 2015, 283: 234–245. doi:10.1016/j.powtec.2015.04.053.
↑  Moul JW. . Cancer. August 2009, 115 (15): 3376–8. PMID 19484788. S2CID 5670663. doi:10.1002/cncr.24393 .
↑  Stuhan MA. . ASHP. 2 April 2013: 268–  [2016-11-05]. ISBN 978-1-58528-360-6. （原始内容存档于2023-01-14）.
↑  Allan GF, Sui Z. . Nucl Recept Signal. 2003, 1: e009. PMC 1402218 . PMID 16604181. doi:10.1621/nrs.01009.
↑   (PDF). AstraZeneca.   [2024-05-09]. （原始内容存档 (PDF)于2021-03-06）.
1 2  Campbell T. . The Motley Fool. 2014-01-22  [2016-07-20]. （原始内容存档于2016-08-26）. [...] the most commonly prescribed treatment for metastatic castration resistant prostate cancer: bicalutamide. That was sold as AstraZeneca's billion-dollar-a-year drug Casodex before losing patent protection in 2008. AstraZeneca still generates a few hundred million dollars in sales from Casodex, [...]
↑  . Press Release. AstraZeneca, Actavis. 2008-07-10  [2024-05-09]. （原始内容存档于2021-08-28）.
↑  Hermkens PH, Kamp S, Lusher S, Veeneman GH. . IDrugs. July 2006, 9 (7): 488–94. PMID 16821162. doi:10.2174/0929867053764671.